 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| 12» |
- || avenciguat (BI 685509) / Boehringer Ingelheim
Trial completion: A Study in Healthy People to Compare Two Different Tablets of BI 685509 and to Test How Food and Esomeprazole Influence the Amount of BI 685509 in the Blood (clinicaltrials.gov) - Mar 21, 2024
P1, N=16, Completed, Sponsor: Boehringer Ingelheim
Active, not recruiting --> Completed
- || Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim, avenciguat (BI 685509) / Boehringer Ingelheim
Enrollment closed, Combination therapy: A Study to Test Whether BI 685509 Alone or in Combination With Empagliflozin Helps People With Liver Cirrhosis Caused by Viral Hepatitis or Non-alcoholic Steatohepatitis (NASH) Who Have High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver) (clinicaltrials.gov) - Mar 6, 2024
P2, N=80, Active, not recruiting, Sponsor: Boehringer Ingelheim
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- avenciguat (BI 685509) / Boehringer Ingelheim
VITALISSCE (Poster Area) - Feb 13, 2024 - Abstract #SSWC2024SSWC_349;
P2
Recruiting --> Active, not recruiting The VITALISScE
- || avenciguat (BI 685509) / Boehringer Ingelheim
Enrollment closed: A Study in Healthy People to Compare Two Different Tablets of BI 685509 and to Test How Food and Esomeprazole Influence the Amount of BI 685509 in the Blood (clinicaltrials.gov) - Feb 9, 2024
P1, N=16, Active, not recruiting, Sponsor: Boehringer Ingelheim
The VITALISScE Recruiting --> Active, not recruiting
- BI 685509 / Boehringer Ingelheim
Bi 685509: a Potent Activator of Soluble Guanylate Cyclase as a Novel Treatment of Vasculopathy and Fibrosis in Systemic Sclerosis () - Feb 8, 2024 - Abstract #CRAAHPA2024CRA_AHPA_116;
In the mouse model of bleomycin-induced skin and lung fibrosis, sGC activation via BI 685509 resulted in significant improvement in skin thickness and lung fibrosis, comparable to mice treated with Nintedanib (60mg/kg) or Riociguat (1 mg/kg). Collectively, these results point to the use of the sGC activator BI 685509 as a novel treatment for SSc and suggests potential superior effects vs. sGC stimulators like Riociguat in this autoimmune disease.
- || avenciguat (BI 685509) / Boehringer Ingelheim
Enrollment open: A Study in Healthy People to Compare Two Different Tablets of BI 685509 and to Test How Food and Esomeprazole Influence the Amount of BI 685509 in the Blood (clinicaltrials.gov) - Jan 29, 2024
P1, N=16, Recruiting, Sponsor: Boehringer Ingelheim
Collectively, these results point to the use of the sGC activator BI 685509 as a novel treatment for SSc and suggests potential superior effects vs. sGC stimulators like Riociguat in this autoimmune disease. Not yet recruiting --> Recruiting
- || avenciguat (BI 685509) / Boehringer Ingelheim
Enrollment open: A Study to Test Whether Avenciguat Helps People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver) Who Had Bleeding in the Esophagus or Fluid Accumulation in the Belly (clinicaltrials.gov) - Jan 23, 2024
P2, N=40, Recruiting, Sponsor: Boehringer Ingelheim
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- || avenciguat (BI 685509) / Boehringer Ingelheim
New P1 trial: A Study in Healthy People to Compare Two Different Tablets of BI 685509 and to Test How Food and Esomeprazole Influence the Amount of BI 685509 in the Blood (clinicaltrials.gov) - Jan 5, 2024
P1, N=16, Not yet recruiting, Sponsor: Boehringer Ingelheim
- || BI 685509 / Boehringer Ingelheim
P1 data, PK/PD data, Journal: Safety and pharmacokinetics of BI 685509, a soluble guanylyl cyclase activator, in patients with cirrhosis: A randomized Phase Ib study. (Pubmed Central) - Oct 31, 2023
P1
BI 685509 was generally well tolerated, with 3 serious, not drug-related AEs reported in patients with CP-B cirrhosis. In patients with CP-A cirrhosis, portal-systemic shunt fraction in the exploratory efficacy analysis was reduced by 2
- || avenciguat (BI 685509) / Boehringer Ingelheim
Trial completion date, Trial primary completion date: A Study to Test Whether Two Different Doses of Avenciguat Help People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Live (clinicaltrials.gov) - Oct 18, 2023
P2, N=78, Recruiting, Sponsor: Boehringer Ingelheim
In patients with CP-A cirrhosis, portal-systemic shunt fraction in the exploratory efficacy analysis was reduced by 2 Trial completion date: Jul 2024 --> Oct 2024 | Trial primary completion date: Jun 2024 --> Sep 2024
- || avenciguat (BI 685509) / Boehringer Ingelheim
New P2 trial: A Study to Test Whether Avenciguat Helps People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver) Who Had Bleeding in the Esophagus or Fluid Accumulation in the Belly (clinicaltrials.gov) - Oct 13, 2023
P2, N=40, Not yet recruiting, Sponsor: Boehringer Ingelheim
- |||| avenciguat (BI 685509) / Boehringer Ingelheim
Trial completion: A Study to Test the Effect of Different Doses of BI 685509 on Kidney Function in People With Chronic Kidney Disease (clinicaltrials.gov) - Oct 3, 2023
P2, N=261, Completed, Sponsor: Boehringer Ingelheim
Trial completion date: Jul 2024 --> Oct 2024 | Trial primary completion date: Jun 2024 --> Sep 2024 Active, not recruiting --> Completed
- || Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim, avenciguat (BI 685509) / Boehringer Ingelheim
Trial completion date, Trial primary completion date, Combination therapy: A Study to Test Whether BI 685509 Alone or in Combination With Empagliflozin Helps People With Liver Cirrhosis Caused by Viral Hepatitis or Non-alcoholic Steatohepatitis (NASH) Who Have High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver) (clinicaltrials.gov) - Sep 18, 2023
P2, N=80, Recruiting, Sponsor: Boehringer Ingelheim
Active, not recruiting --> Completed Trial completion date: Feb 2024 --> Jun 2024 | Trial primary completion date: Jan 2024 --> May 2024
- || avenciguat (BI 685509) / Boehringer Ingelheim
Trial completion date, Trial primary completion date: A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms (clinicaltrials.gov) - Aug 9, 2023
P2, N=200, Recruiting, Sponsor: Boehringer Ingelheim
Trial completion date: Feb 2024 --> Jun 2024 | Trial primary completion date: Jan 2024 --> May 2024 Trial completion date: May 2025 --> Nov 2025 | Trial primary completion date: Apr 2025 --> Oct 2025
- || avenciguat (BI 685509) / Boehringer Ingelheim
Trial completion date, Trial primary completion date: A Study to Test Whether Two Different Doses of Avenciguat Help People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Live (clinicaltrials.gov) - Jun 27, 2023
P2, N=105, Recruiting, Sponsor: Boehringer Ingelheim
Trial completion date: May 2025 --> Nov 2025 | Trial primary completion date: Apr 2025 --> Oct 2025 Trial completion date: Mar 2024 --> Jul 2024 | Trial primary completion date: Feb 2024 --> Jun 2024
- | BI 685509 / Boehringer Ingelheim
Preclinical, Journal: Soluble Guanylyl Cyclase Activator BI 685509 Reduces Portal Hypertension and Portosystemic Shunting in a Rat Thioacetamide-Induced Cirrhosis Model. (Pubmed Central) - Jun 19, 2023
Significance Statement BI 685509 is an NO-independent sGC activator that was tested in a preclinical rat model of thioacetamide-induced nodular, liver fibrosis, portal hypertension, and portal systemic shunting. BI 685509 reduced liver fibrosis, portal hypertension, and portal-systemic shunting in a dose-dependent manner, supporting its clinical assessment to treat portal hypertension in patients with cirrhosis.
- || BI 685509 / Boehringer Ingelheim
PK/PD data, Journal: Safety, tolerability, pharmacodynamics and pharmacokinetics of the soluble guanylyl cyclase activator BI 685509 in patients with diabetic kidney disease: A randomized trial. (Pubmed Central) - May 26, 2023
P1
BI 685509 was generally well tolerated. Effects on UACR lowering merit further investigation.
- ||| avenciguat (BI 685509) / Boehringer Ingelheim
Enrollment closed: A Study to Test the Effect of Different Doses of BI 685509 on Kidney Function in People With Chronic Kidney Disease (clinicaltrials.gov) - Apr 28, 2023
P2, N=261, Active, not recruiting, Sponsor: Boehringer Ingelheim
Effects on UACR lowering merit further investigation. Recruiting --> Active, not recruiting
- | enalapril / Generic mfg., BI 685509 / Boehringer Ingelheim
Journal: The Novel, Clinical Stage Soluble Guanylate Cyclase Activator BI 685509 Protects from Disease Progression in Models of Renal Injury and Disease. (Pubmed Central) - Mar 2, 2023
In BI 685509 reduced proteinuria and glomerulosclerosis in the ZSF1 rat, a model of DKD, and reduced tubulointerstitial fibrosis in a rat 7-Day UUO model. Thus, BI 685509 is a promising new therapeutic agent and is currently in Phase II clinical trials for CKD and DKD.
- || Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim, avenciguat (BI 685509) / Boehringer Ingelheim
Trial completion date, Trial primary completion date, Combination therapy: A Study to Test Whether BI 685509 Alone or in Combination With Empagliflozin Helps People With Liver Cirrhosis Caused by Viral Hepatitis or Non-alcoholic Steatohepatitis (NASH) Who Have High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver) (clinicaltrials.gov) - Jan 26, 2023
P2, N=80, Recruiting, Sponsor: Boehringer Ingelheim
Thus, BI 685509 is a promising new therapeutic agent and is currently in Phase II clinical trials for CKD and DKD. Trial completion date: Jul 2023 --> Nov 2023 | Trial primary completion date: Jun 2023 --> Oct 2023
- |||| avenciguat (BI 685509) / Boehringer Ingelheim
Trial completion: A Study to Test the Effect of Different Doses of BI 685509 on Kidney Function in People With Diabetic Kidney Disease (clinicaltrials.gov) - Jan 11, 2023
P2, N=243, Completed, Sponsor: Boehringer Ingelheim
Trial completion date: Jul 2023 --> Nov 2023 | Trial primary completion date: Jun 2023 --> Oct 2023 Active, not recruiting --> Completed
- ||| avenciguat (BI 685509) / Boehringer Ingelheim
Enrollment change, Trial completion date, Trial primary completion date: A Study to Test Whether Two Different Doses of Avenciguat Help People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Live (clinicaltrials.gov) - Dec 14, 2022
P2, N=105, Recruiting, Sponsor: Boehringer Ingelheim
Active, not recruiting --> Completed N=150 --> 105 | Trial completion date: Nov 2023 --> Mar 2024 | Trial primary completion date: Oct 2023 --> Feb 2024
- ||| avenciguat (BI 685509) / Boehringer Ingelheim
Enrollment open: A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms (clinicaltrials.gov) - Dec 1, 2022
P2, N=200, Recruiting, Sponsor: Boehringer Ingelheim
N=150 --> 105 | Trial completion date: Nov 2023 --> Mar 2024 | Trial primary completion date: Oct 2023 --> Feb 2024 Not yet recruiting --> Recruiting
- || avenciguat (BI 685509) / Boehringer Ingelheim
Trial completion: A Study in Healthy Men to Test How BI 685509 is Processed in the Body (clinicaltrials.gov) - Nov 28, 2022
P1, N=12, Completed, Sponsor: Boehringer Ingelheim
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- || avenciguat (BI 685509) / Boehringer Ingelheim
Enrollment closed: A Study in Healthy Men to Test How BI 685509 is Processed in the Body (clinicaltrials.gov) - Nov 7, 2022
P1, N=12, Active, not recruiting, Sponsor: Boehringer Ingelheim
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- BI 685509 / Boehringer Ingelheim
SOLUBLE GUANYLATE CYCLASE ACTIVATOR BI 685509 REDUCES PORTAL HYPERTENSION AND PORTOSYSTEMIC SHUNTING IN A RAT THIOACETAMIDE-INDUCED CIRRHOSIS MODEL () - Oct 23, 2022 - Abstract #AASLD2022AASLD_1856;
The sGC activator, BI 685509, improved hepatic and extrahepatic outcomes of cirrhosis pathophysiology in a preclinical rat model. These data support the clinical investigation of BI 685509 for the treatment of PHT in patients with cirrhosis.
- BI 685509 / Boehringer Ingelheim
The Novel, Clinical Stage Soluble Guanylate Cyclase Activator BI 685509 Slows the Progression of Diabetic Nephropathy in db/db Mice (Exhibit Hall, Orange County Convention Center, West Building) - Oct 13, 2022 - Abstract #KIDNEYWEEK2022KIDNEY_WEEK_2107;
Conclusion These results suggest that treatment with BI-685509 for 6 weeks slow the progression of diabetic nephropathy in db/db mice via multiple actions and underscores its therapeutic potential in CKD and DKD. Currently, BI-685509 is in Phase II clinical trial to be tested for CKD and DKD.
- |||| avenciguat (BI 685509) / Boehringer Ingelheim
New P2 trial: A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms (clinicaltrials.gov) - Sep 29, 2022
P2, N=200, Not yet recruiting, Sponsor: Boehringer Ingelheim
- || avenciguat (BI 685509) / Boehringer Ingelheim
Enrollment open: A Study in Healthy Men to Test How BI 685509 is Processed in the Body (clinicaltrials.gov) - Sep 16, 2022
P1, N=12, Recruiting, Sponsor: Boehringer Ingelheim
Currently, BI-685509 is in Phase II clinical trial to be tested for CKD and DKD. Not yet recruiting --> Recruiting
- || avenciguat (BI 685509) / Boehringer Ingelheim
New P1 trial: A Study in Healthy Men to Test How BI 685509 is Processed in the Body (clinicaltrials.gov) - Aug 25, 2022
P1, N=12, Not yet recruiting, Sponsor: Boehringer Ingelheim
- ||| avenciguat (BI 685509) / Boehringer Ingelheim
Enrollment closed: A Study to Test the Effect of Different Doses of BI 685509 on Kidney Function in People With Diabetic Kidney Disease (clinicaltrials.gov) - Jun 16, 2022
P2, N=233, Active, not recruiting, Sponsor: Boehringer Ingelheim
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||| Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim, avenciguat (BI 685509) / Boehringer Ingelheim
Enrollment open, Combination therapy: A Study to Test Whether BI 685509 Alone or in Combination With Empagliflozin Helps People With Liver Cirrhosis Caused by Viral Hepatitis or Non-alcoholic Steatohepatitis (NASH) Who Have High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver) (clinicaltrials.gov) - Jun 7, 2022
P2, N=80, Recruiting, Sponsor: Boehringer Ingelheim
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- || avenciguat (BI 685509) / Boehringer Ingelheim
Trial completion date, Trial primary completion date: A Study to Test the Effect of Different Doses of BI 685509 on Kidney Function in People With Chronic Kidney Disease (clinicaltrials.gov) - Apr 20, 2022
P2, N=240, Recruiting, Sponsor: Boehringer Ingelheim
Not yet recruiting --> Recruiting Trial completion date: Feb 2023 --> Aug 2023 | Trial primary completion date: Jan 2023 --> Jul 2023
- |||| Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim, avenciguat (BI 685509) / Boehringer Ingelheim
New P2 trial, Combination therapy: A Study to Test Whether BI 685509 Alone or in Combination With Empagliflozin Helps People With Liver Cirrhosis Caused by Viral Hepatitis or Non-alcoholic Steatohepatitis (NASH) Who Have High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver) (clinicaltrials.gov) - Mar 16, 2022
P2, N=80, Not yet recruiting, Sponsor: Boehringer Ingelheim
- || avenciguat (BI 685509) / Boehringer Ingelheim
Trial completion, Trial completion date, Trial primary completion date: A Study in Healthy Men to Find the Best Formulation of BI 685509 and to Test How it is Taken up in the Body (clinicaltrials.gov) - Mar 8, 2022
P1, N=39, Completed, Sponsor: Boehringer Ingelheim
Trial completion date: Feb 2023 --> Aug 2023 | Trial primary completion date: Jan 2023 --> Jul 2023 Active, not recruiting --> Completed | Trial completion date: May 2022 --> Feb 2022 | Trial primary completion date: May 2022 --> Feb 2022
- ||| avenciguat (BI 685509) / Boehringer Ingelheim
Enrollment open: A Study to Test Whether Two Different Doses of Avenciguat Help People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Live (clinicaltrials.gov) - Feb 7, 2022
P2, N=150, Recruiting, Sponsor: Boehringer Ingelheim
Active, not recruiting --> Completed | Trial completion date: May 2022 --> Feb 2022 | Trial primary completion date: May 2022 --> Feb 2022 Not yet recruiting --> Recruiting
- || avenciguat (BI 685509) / Boehringer Ingelheim
Trial completion date, Trial primary completion date: A Study to Test the Effect of Different Doses of BI 685509 on Kidney Function in People With Chronic Kidney Disease (clinicaltrials.gov) - Jan 25, 2022
P2, N=240, Recruiting, Sponsor: Boehringer Ingelheim
Not yet recruiting --> Recruiting Trial completion date: Aug 2022 --> Feb 2023 | Trial primary completion date: Jul 2022 --> Jan 2023
- || avenciguat (BI 685509) / Boehringer Ingelheim
Enrollment closed: A Study in Healthy Men to Find the Best Formulation of BI 685509 and to Test How it is Taken up in the Body (clinicaltrials.gov) - Jan 11, 2022
P1, N=40, Active, not recruiting, Sponsor: Boehringer Ingelheim
Trial completion date: Aug 2022 --> Feb 2023 | Trial primary completion date: Jul 2022 --> Jan 2023 Recruiting --> Active, not recruiting
- |||| avenciguat (BI 685509) / Boehringer Ingelheim
New P2 trial: A Study to Test Whether Two Different Doses of Avenciguat Help People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Live (clinicaltrials.gov) - Dec 16, 2021
P2, N=150, Not yet recruiting, Sponsor: Boehringer Ingelheim
- BI 685509 / Boehringer Ingelheim
[VIRTUAL] PHASE IB STUDY OF THE SOLUBLE GUANYLATE CYCLASE ACTIVATOR BI 685509 IN PATIENTS WITH MILD AND MODERATE HEPATIC IMPAIRMENT () - Oct 21, 2021 - Abstract #AASLD2021AASLD_2312;
P1
Exposure after dosing with BI 685509 was similar between patient groups . The portosystemic shunt fraction was reduced at high doses of BI 685509.
- BI 685509 / Boehringer Ingelheim
[VIRTUAL] BI 685509 IMPROVES HEPATIC FUNCTION IN SUBJECTS WITH CHILD–PUGH A CIRRHOSIS AND A LIVER STIFFNESS MEASUREMENT OF >15 KPA: RESULTS FROM THE HEPQUANT SHUNT TEST () - Oct 21, 2021 - Abstract #AASLD2021AASLD_2304;
P1
BI 685509 improved effective hepatic perfusion; there was a dose-dependent increase in first-pass extraction of d4-CA that was significant at 3 mg BID. The HepQuant SHUNT test successfully defined differences in baseline disease severity between treatment arms, detecting early treatment effects and defining dose-response using small sample sizes.
- BI 685509 / Boehringer Ingelheim
[VIRTUAL] Phase Ib Study of the Soluble Guanylate Cyclase Activator BI 685509 in Patients with Diabetic Kidney Disease () - Oct 17, 2021 - Abstract #KIDNEYWEEK2021KIDNEY_WEEK_2108;
P1
Conclusion BI 685509 treatment was generally well-tolerated with over 50% of patients in the 3 mg QD and 3 mg TID dose groups appearing to show a response in UACR 10h . Proportion of responders (≥20% decrease from baseline in UACR)
- BI 690517 / Boehringer Ingelheim
[VIRTUAL] Phase 1c Study of the Aldosterone Synthase Inhibitor BI 690517 in Diabetic Patients with Kidney Disease () - Oct 17, 2021 - Abstract #KIDNEYWEEK2021KIDNEY_WEEK_2107;
P1
Methods Patients with type 1 or type 2 diabetes, estimated glomerular filtration rate (eGFR) 20–75 mL/min/1.73m 2 and urine albumin creatinine ratio (UACR) 200–3500 mg/g, receiving stable angiotensin receptor blocker/angiotensin-converting enzyme inhibitor treatment were randomised to receive daily oral BI 690517 (3/10/40 mg), eplerenone (25–50 mg) or PBO for 28 days...Changes seen in SBP did not differ between PBO and BI 685509 dose groups...Conclusion BI 690517 was generally well tolerated and appears to have an early effect on UACR, with over 50% of treated patients being classed as responders. These data need to be confirmed in larger studies.
- || avenciguat (BI 685509) / Boehringer Ingelheim
Enrollment open: A Study in Healthy Men to Find the Best Formulation of BI 685509 and to Test How it is Taken up in the Body (clinicaltrials.gov) - Jul 12, 2021
P1, N=40, Recruiting, Sponsor: Boehringer Ingelheim
These data need to be confirmed in larger studies. Not yet recruiting --> Recruiting
- || avenciguat (BI 685509) / Boehringer Ingelheim
New P1 trial: A Study in Healthy Men to Find the Best Formulation of BI 685509 and to Test How it is Taken up in the Body (clinicaltrials.gov) - Jun 15, 2021
P1, N=40, Not yet recruiting, Sponsor: Boehringer Ingelheim
- ||| avenciguat (BI 685509) / Boehringer Ingelheim
Trial completion: A Study to Test How Different Doses of BI 685509 Are Tolerated in Patients With Liver Problems (clinicaltrials.gov) - Jun 10, 2021
P1, N=64, Completed, Sponsor: Boehringer Ingelheim
Not yet recruiting --> Recruiting Recruiting --> Completed
- |||| avenciguat (BI 685509) / Boehringer Ingelheim
Enrollment open: A Study to Test the Effect of Different Doses of BI 685509 on Kidney Function in People With Diabetic Kidney Disease (clinicaltrials.gov) - May 7, 2021
P2, N=240, Recruiting, Sponsor: Boehringer Ingelheim
Recruiting --> Completed Not yet recruiting --> Recruiting
- |||| avenciguat (BI 685509) / Boehringer Ingelheim
Enrollment open: A Study to Test the Effect of Different Doses of BI 685509 on Kidney Function in People With Chronic Kidney Disease (clinicaltrials.gov) - May 4, 2021
P2, N=240, Recruiting, Sponsor: Boehringer Ingelheim
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||||| avenciguat (BI 685509) / Boehringer Ingelheim
New P2 trial: A Study to Test the Effect of Different Doses of BI 685509 on Kidney Function in People With Diabetic Kidney Disease (clinicaltrials.gov) - Feb 10, 2021
P2, N=240, Not yet recruiting, Sponsor: Boehringer Ingelheim
- ||||| avenciguat (BI 685509) / Boehringer Ingelheim
New P2 trial: A Study to Test the Effect of Different Doses of BI 685509 on Kidney Function in People With Chronic Kidney Disease (clinicaltrials.gov) - Feb 3, 2021
P2, N=240, Not yet recruiting, Sponsor: Boehringer Ingelheim